

C-reactive protein and procalcitonin levels in prostate cancer

Abdullah Ilktac¹  | Senad Kalkan¹  | Selahattin Caliskan² 

¹Bezmialem Vakif Universitesi Tip Fakultesi, Istanbul, Turkey

²Department of Urology, Reyap Special Hospital, Istanbul, Turkey

Correspondence

Selahattin Caliskan, İstanbul Reyap Hospital, Istanbul, Turkey.

Email: dr.selahattincaliskan@gmail.com

Abstract

Aim: Prostate cancer (PCa) is one of the most common cancers among men in the world. Prostate-specific antigen is the most used biomarker for PCa diagnosis. In this study, we aimed to measure the procalcitonin (PCT) and C-reactive protein (CRP) levels in patients with PCa.

Methods: The patients who underwent transrectal prostate biopsy and transurethral prostate surgery in the last 4 years were included in the study. The patients were divided into two groups according to the pathology reports, group1; benign prostate hyperplasia and group2; prostate cancer. MedCalc Statistical Software version 17.6 was used for statistical analyses.

Results: The current study includes 149 patients. There were 118 patients in group 1 and 31 patients in group 2. The mean age of the patients was 66.85 and 69.41 years in groups respectively. Serum CRP and PCT levels were 3.33 and 0.01 in group 1 and 0.04 in group 2. Serum PCT levels were significantly higher in patients with PCa.

Conclusion: We found that the elevated procalcitonin level was associated with prostate cancer. Further studies are needed to define the relationship between procalcitonin and prostate cancer.

1 | INTRODUCTION

Prostate cancer(PCa) is one of the most common cancers among males in the world and the fifth most common malignancy in the general population.¹ Serum prostate-specific antigen (PSA) testing is the most commonly used test for the diagnosis and screening of PCa.² The patients may be diagnosed as from clinically indolent to metastatic disease.³ Digital rectal examination (DRE) and PSA testing are important for early diagnosis of PCa.⁴ Unfortunately PSA is not cancer-specific marker, it is organ-specific; so elevated levels are seen in benign diseases such as prostatitis, benign prostate hyperplasia and urinary retention.^{1,4} Despite its adequate sensitivity, the use of PSA testing is limited and additional serum testing derived from PSA (PSA density, free/total PSA, PSA velocity) and new biomarkers (prostate health index, four kallikrein and procalcitonin) were investigated for diagnosis of PCa.^{2,4,5}

C-reactive protein (CRP) is an acute-phase protein that is produced in the liver.⁶ High levels of CRP (1000 fold) are usually associated with microbial infection, trauma, infarction and autoimmune

diseases. In addition, elevated CRP levels have been linked to poor prognosis in some malignancies; oral squamous cell carcinoma, esophageal carcinoma, non-small and small cell lung cancers, melanoma, hepatocellular carcinoma, breast cancer, endometrial cancer, urogenital cancers. Procalcitonin (PCT) is produced by thyroid C-cells and some neuroendocrine cells and it is a precursor of calcitonin.² In the systemic inflammatory reaction and some malignancies such as thyroid and renal cell carcinomas have an association with PCT levels. In this study, we aimed to measure CRP and PCT levels in prostate cancer patients and compared the patients without malignancy.

2 | METHODS

The patients who underwent transrectal prostate biopsy and transurethral prostate surgery between January 2016 and June 2019 were included in the study. The patients' history of radiotherapy, dutasteride therapy, malignancy, chronic prostatitis and high level

of PSA (>100 ng/mL) were excluded. The biopsy was made under local anaesthesia with a lateral decubitus position at least 10 cores and prostate surgery was made under spinal or general anaesthesia with lithotomy position. The PSA, free PSA, CRP, PCT levels were measured before the procedures. After the pathological examination, the patients were divided into two groups. The patients with benign prostate hyperplasia were in Group 1 and PCa was in group 2. The results of high grade prostatic intraepithelial neoplasia (n:3) and atypical small acinar proliferation(n:4) were excluded from the study.

Distribution normality was analyzed with the Kolmogorov-Smirnov test. The normal distribution variable was compared with independent t test and the others were compared with Mann-Whitney U test. The chi-squared test was used for percentage values. Data were expressed as mean \pm standard deviation for PSA, free PSA, CRP, PCT and sedimentation median for the age, neutrophil and white blood cell and $P < .05$ as considered with statistical significance. The receiver operating characteristic(ROC) curves were analyzed to assess the diagnostic utility total PSA,CRP and PCT levels in different PSA levels (≤ 10 and >10 ng/mL). Statistical analyses were performed using the demo version of MedCalc Statistical Software version17.6 (MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2017).

3 | RESULTS

There were 149 patients in this study. Of these patients; 118 patients were in Group 1 and 31 patients were in Group 2. The mean age of the patients was 66.85 ± 8.19 and 69.41 ± 6.20 years in groups, respectively ($P = .10$). Table 1 shows the patients' characteristics. The PSA level was significantly higher in group 2. Serum CRP

TABLE 1 The general characteristics of the patients in groups

	Group 1	Group 2	P
n	118 (79.2)	31 (20.8)	
Age (y)	66.85 ± 8.19	69.41 ± 6.20	.10
WBC ($\times 10^6/L$)	7455 ± 1917	7635 ± 1905	.64
Neutrophil ($\times 10^6/L$)	4759 ± 1622	4801 ± 1399	.89
Lymphocyte ($\times 10^6/L$)	2005 ± 762	2149 ± 613	.33
PSA (ng/mL)	5.55	10.2	<.05*
fPSA (ng/mL)	1.12	5	<.05*
CRP (mg/L)	3.3	4.07	.08
PCT (ng/mL)	0.01	0.04	<.05*
Sedimentation (mm/saat)	4	5	.19
Sedimentation 1. Hour	11	15	.17

Abbreviations: CRP, C-reactive protein; PCT, procalcitonin; PSA, prostate-specific antigen; WBC, white blood cell.

*statistically significant.

What's known

- Prostate cancer is the second most common cancer among elderly men. Prostate-specific antigen testing is usually used in screening and diagnosis.
- Unfortunately, PSA is not cancer-specific and new biomarkers are needed for prostate cancer management.

What's new

- Procalcitonin is a precursor of calcitonin which is produced by thyroid C-cells and some neuroendocrine cells.
- The elevated level of procalcitonin is associated with bacteremia and sepsis.
- In this study, we investigated the procalcitonin levels in prostate cancer.

and PCT levels were 3.3 mg/L and 0.01 ng/ml in group 1, 4.07 mg/L and 0.04 ng/ml in group 2 ($P = .08$ for CRP and $P < .05$ for PCT).

The diagnosis was made by prostate biopsy in 92 patients and prostate surgery in 57 patients (Table 2). There was significant difference for the diagnosis method in groups ($P < .05$). In group 2, GS 6 and 7 were detected in 11 and 7 patients, respectively. Gleason score was reported as 8,9 and 10 in 7, 4 and 2 patients.

4 | DISCUSSION

PCa is the most common malignancy in men older than 60 years and the second most common cause of cancer deaths after lung cancer in worldwide.⁷ The main cause of PCa is unknown but age, genetic factors, diet and environmental factors are focused on the etiology.⁸ Serum PSA testing is the most widely accepted and used biomarker for prostatic diseases especially PCa.⁹ But PSA is not cancer-specific marker, increases in benign prostate diseases and there is no threshold value of PSA for cancer diagnosis.¹ In general, PSA over 4 ng/mL is recommended for biopsy, the cancer detection rate is between 20% and 25% in patients with a PSA value of 4-10 ng/mL. In our previous study, the cancer detection rate was 22.3, 34.5 and 54.2% in patients with PSA level of 4-10, 10.01-20 and 20.01-50 ng/mL, respectively.¹⁰ To reduce the unnecessary biopsies, new molecules and markers which have higher positive predictive value than PSA have been investigated.¹ Prostate health index, four kallikrein score test, PSA density and velocity, free/total PSA ratio, PCA3 marker

TABLE 2 Comparison of the diagnostic methods

	Group 1	Group 2	P
Prostate biopsy n, %	65 (55.1)	27 (87.1)	<.05
Transurethral surgery n,%	53 (44.9)	4(12.9)	

were used to differentiate benign prostate diseases from PCa.⁴ We found that the free/total PSA ratio has significant diagnostic efficacy for PCa diagnosis in the PSA level 4.01-10 ng/mL.⁵

C-reactive protein is an acute phase protein that is mainly produced in liver and rarely in atherosclerotic lesions, kidney, neurons and alveolar macrophages in the body.¹¹ Synthesis of CRP is associated with interleukin 6 (IL-6) secretion from macrophages and T-cells. In the inflammation, activation of IL-6 increases the serum level of CRP. Systemic inflammation has an important role in cancer initiation, promotion, progression, metastasis stimulates endocrine cells to hyperplasia and neoplastic transformation.¹² C-reactive protein can predict urological cancers such as renal cell carcinoma, bladder cancer, prostate cancer and upper urinary tract cancers. In contrast, the authors found no association between PCa risk and CRP levels.¹³ The authors demonstrated that CRP was a prognostic factor in PCa and correlated with patients who had bone metastasis than without metastasis.¹²

Procalcitonin is a 116 amino-acid protein with a weight of 13 kDa which is a precursor of the calcitonin hormone.¹⁴ During bacterial and fungal infections, circulating and cytokines increase the level of PCT and it has been investigated as a marker for bacteremia and sepsis.^{14,15} The studies showed that inflammation plays an important role in tumor genesis and relationship between PCT and medullary carcinoma and non-small cell lung cancer was investigated.^{16,17} In addition, the authors reported that PCT value may be a biomarker for the prediction of localized clear cell carcinoma.¹⁵ The authors from Turkey found that PCT can be used to diagnose PCa with a PSA level of 2-20 ng/mL.² We found a high diagnostic efficacy of PCT in patients with a PSA level >10 ng/mL and no significant difference between PSA and PCT.

There are some limitations in the current study. This study includes a small number of patients from one center and the parameters (CRP, PCT) were not checked again after first measuring the levels. The stage of the patients with PCa was not homogenous.

We found that serum PCT levels were higher in patients with prostate cancer. If further studies support our findings serum PCT can be a new biomarker to diagnose prostate cancer in the future.

ACKNOWLEDGEMENTS

None.

DISCLOSURE

The authors have declared no conflicts of interest for this article.

ORCID

Abdullah Ilktac  <https://orcid.org/0000-0002-0599-5436>

Senad Kalkan  <https://orcid.org/0000-0001-6000-8504>

Selahattin Caliskan  <https://orcid.org/0000-0001-7864-8374>

REFERENCES

- Selvi I, Basar H, Baydilli N, Murat K, Kaymaz O. The importance of plasma arginine level and its downstream metabolites in diagnosing prostate cancer. *Int Urol Nephrol*. 2019;51:1975-1983.
- Canat L, Atalay HA, Can O, Alkan I, Otuntemur A. Serum procalcitonin levels in prostate cancer: a new biomarker? *Urol J*. 2018;85:46-50.
- Verep S, Erdem S, Ozluk Y, Kilicaslan I, Sanli O, Ozcan F. The pathological upgrading after radical prostatectomy in low-risk prostate cancer patients who are eligible for active surveillance: how safe is it to depend on bioptic pathology? *Prostate*. 2019;79:1523-1529.
- Ceylan C, Doluoglu OG, Yahşi S. A different perspective: can urine pH be important in the diagnosis of prostate cancer? *Urologia*. 2019;31:391560319865724.19-22.
- Caliskan S. Diagnostic efficacy of free prostate-specific antigen/total prostate-specific antigen ratio for the diagnosis of prostate cancer in low concentration (≤ 4 ng/ml) and intermediate levels of total prostate-specific antigen (4.01-10.0 ng/ml). *J Can Res Ther*. 2017;13:279-283.
- Schnoeller TJ, Steinestel J, Steinestel K, Jentzmik F, Schrader AJ. Do preoperative serum C-reactive protein levels predict the definitive pathological stage in patients with clinically localized prostate cancer? *Int Urol Nephrol*. 2015;47:765-770.
- Memis A, Ugurlu O, Ozden C, Oztekin CV, Aktas BK, Akdemir AO. The correlation among the percentage of positive biopsy cores from the dominant side of prostate, adverse pathology, and biochemical failure after radical prostatectomy. *Kaohsiung J Med Sci*. 2011;27:307-313.
- Benli E, Cirakoglu A, Ayyıldız SN, Yüce A. Comparison of serum uric acid levels between prostate cancer patients and a control group. *Cent European J Urol*. 2018;71:242-247.
- Elzanaty S, Rezanezhad B, Borgquist R. Association between PSA levels and biomarkers of subclinical systemic inflammation in middle-aged healthy men from the general population. *Curr Urol*. 2016;9:148-152.
- Çalışkan S. Prevalence of prostate cancer among Turkish men with prostate-specific antigen level of ≤ 100 ng/ml. *J Can Res Ther*. 2018;14:1256-1259.
- Schimmack S, Yang Y, Felix K, et al. C-reactive protein (CRP) promotes malignant properties in pancreatic neuroendocrine neoplasms. *Endocr Connect*. 2019;8:1007-1019.
- Dai J, Tang K, Xiao W, et al. Prognostic significance of C-reactive protein in urological cancers: a systematic review and meta-analysis. *Asian Pac J Cancer Prev*. 2014;15:3369-3375.
- Van Hemelrijck M, Jungner I, Walldius G, et al. Risk of prostate cancer is not associated with levels of C-reactive protein and other commonly used markers of inflammation. *Int J Cancer*. 2011;129:1485-1492.
- Sbrana A, Torchio M, Comolli G, Antonuzzo A, Danova M; Italian Network for Supportive Care in Oncology (NICSO). Use of procalcitonin in clinical oncology: a literature review. *New Microbiol*. 2016;39:174-180.
- Hamidi N, Gokce MI, Suer E, Baltacı S. Evaluation of increased preoperative serum high sensitive C-reactive protein and procalcitonin levels on grade and stage of clear cell renal cell carcinoma. *Clin Nephrol*. 2015;83:225-230.
- Giovanella L, Verburg FA, Imperiali M, Valabrega S, Trimboli P, Ceriani L. Comparison of serum calcitonin and procalcitonin in detecting medullary thyroid carcinoma among patients with thyroid nodules. *Clin Chem Lab Med*. 2013;51:1477-1481.
- Walter MA, Meier C, Radimerski T, et al. Procalcitonin levels predict clinical course and progression-free survival in patients with medullary thyroid cancer. *Cancer*. 2010;116:31-40.

How to cite this article: Ilktac A, Kalkan S, Caliskan S. C-reactive protein and procalcitonin levels in prostate cancer. *Int J Clin Pract*. 2021;75:e13935. <https://doi.org/10.1111/ijcp.13935>